Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora

Damora Therapeutics, Inc.

Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.
Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.
Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.